On January 2, 2018 Alkermes plc (NASDAQ: ALKS) reported that its corporate presentation will be webcast live at the 36th Annual J.P. Morgan Healthcare Conference on Tuesday, Jan. 9, 2018 at 10:30 a.m. PT (1:30 p.m. ET/6:30 p.m. GMT) from the Westin St. Francis Hotel in San Francisco (Press release, Alkermes, JAN 2, 2018, View Source;p=RssLanding&cat=news&id=2324467 [SID1234522811]). The presentation will be followed by a question and answer session that will begin at 11:00 a.m. PT (2:00 p.m. ET/7:00 p.m. GMT). A webcast of both the presentation and question and answer session may be accessed under the Investors tab on www.alkermes.com and will be archived for 14 days.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Alkermes plc is a fully integrated, global biopharmaceutical company developing innovative medicines for the treatment of central nervous system (CNS) diseases. The company has a diversified commercial product portfolio and a substantial clinical pipeline of product candidates for chronic diseases that include schizophrenia, depression, addiction and multiple sclerosis. Headquartered in Dublin, Ireland, Alkermes plc has an R&D center in Waltham, Massachusetts; a research and manufacturing facility in Athlone, Ireland; and a manufacturing facility in Wilmington, Ohio. For more information, please visit Alkermes’ website at www.alkermes.com.

On January 2, 2018 Celgene Corporation (NASDAQ: CELG) reported that during the 36th Annual J.P. Morgan Healthcare Conference on January 8, 2018 at 10:30 a.m. ET, it will present a business update on the Company in addition to preliminary unaudited 2017 financial results (Press release, Celgene, JAN 2, 2018, View Source [SID1234522802]). The presentation and breakout session can be accessed live by webcast and the financial data will be made available in the Investor Relations section of the Company’s website at www.celgene.com.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On January 2, 2018 Alexion Pharmaceuticals (Nasdaq: ALXN) reported that management will present at the 36th Annual J.P. Morgan Healthcare Conference in San Francisco on Monday, January 8, 2018 at 9:00 a.m., PT (12:00 p.m., ET) (Press release, Alexion, JAN 2, 2018, View Source [SID1234522810]). The Q&A breakout session will immediately follow the presentation at 9:30 a.m., PT (12:30 p.m., ET).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

An audio webcast of the presentation and breakout session will be available live. You can access the webcast at: View Source An archived version of the remarks will also be available through the Company’s website for a limited time following the conference.

On January 2, 2018 Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN), a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases, reported that the Company’s management will present an overview and update for the Company, and host investor meetings at the 36th Annual J.P. Morgan Healthcare Conference (Press release, Supernus, FEB 2, 2018, View Source [SID1234522857]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Date: Wednesday, January 10, 2018

Time: 12:00 p.m. PT / 3:00 p.m. ET
Place: Westin St. Francis Hotel, San Francisco, CA

Investors interested in arranging a meeting with the Company’s management during these conferences should contact the conference coordinator.

A live webcast of the presentation can be accessed by visiting ‘Events & Presentations’ in the Investors Section on the Company’s website at www.supernus.com. An archived replay of this webcast will be available for 60 days subsequent to the Company’s presentation.

On January 2, 2018 Genmab A/S (Nasdaq Copenhagen: GEN) reported that its CEO, Jan van de Winkel, Ph.D., will present a company update at the 36th Annual J.P. Morgan Healthcare Conference in San Francisco at 2:00 PM PST on January 10, 2018 (11:00 PM CET) (Press release, Genmab, JAN 2, 2018, View Source [SID1234522803]). A webcast of the presentation will be available on Genmab’s website at View Source

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!